Long title
Clinical trial (phase II) to evaluate the efficacy of MVANP+M1 in a human H3N2 influenza challenge model.
Date receipt dossier
EU record number
FLU10
EudraCT number
2018-004015-49
Company / Sponsor
Vaccitech Limited
Phase
II
Treated organism
Humans
Indication category
Infectious disease
Disease
Influenza virus infection (seasonal flu)
Therapeutic approach
Prevention
Genetic modification
Vaccinia virus Ankara strain expressing nucleoprotein (NP) and Matrix protein (M1) from influenza A H3N2 virus
Method of transfer of nucleic acid of interest
Not applicable
Administered biological material
Recombinant vaccinia virus (MVA) expressing nucleoprotein (NP) and Matrix protein (M1) from influenza A H3N2 virus
Route of administration
Intramuscular
Locations in Belgium
SGS Belgium NV
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
MVA-NP+M1